|
Zika Virus Infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 125 Vero cell host proteins, including cytokines such as CXCL11 and CCL5, interferon stimulated gene 15, and translation initiation factors EIF5A and EIF4G2, are significantly dysregulated after ZIKV infection.
|
30578658 |
2019 |
|
Undifferentiated carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.
|
24569836 |
2014 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
We used cell viability assays, western blotting, immunofluorescence, transwell-matrigel invasion assay, wound-healing assay combined with GC7 (a novel eIF5A-2 inhibitor) treatment or siRNA interference to investigate the role of eIF5A-2 playing in NSCLC chemotherapy.
|
25380840 |
2014 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Importantly, eIF5A mediates PDAC cell migration and invasion by modulating RhoA/ROCK protein expression levels.
|
26483550 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Interestingly, N1-guanyl-1,7-diaminoheptane (GC7), which is an inhibitor for the first step of eIF5A hypusination, was shown to significantly impair the cell proliferation and invasion of primary HCC cells (HepG2 and Hep3B).
|
19998337 |
2010 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of eIF5A-2 was up-regulated following EMT phenotype changes in A549 cells, which correlated with enhanced tumor invasion and metastatic capabilities.
|
23733422 |
2013 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Mechanistically, ARAF mediates the regulation of trophoblast migration and invasion by EIF5A1.
|
30206208 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Most importantly, GC7 (N1-guanyl-1,7-diaminoheptane, an EIF5A1 hypusination inhibitor) could reverse the effect of EIF5A1 upregulation on EOC cell proliferation, migration, and invasion and mutant type EIF5A1<sub>K50A</sub> plasmid [bearing a single point mutation (K50 → A50) that prevents hypusination] had no effects on these malignant behaviors.
|
29428664 |
2018 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest a novel role for miR-331-3p and miR-642-5p in the control of prostate cancer cell growth via the regulation of DOHH expression and eIF5A activity.
|
22908221 |
2012 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The translation factor eIF5A and human cancer.
|
25979826 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Eukaryotic translation initiation factor 5A (EIF5A) promotes cancer metastasis.
|
30761741 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High eIF5A expression is observed in many tumor types and has been linked to cancer metastasis.
|
28549188 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the potential oncogenic role and prognostic significance of eIF5A-2 in the prediction of the survival of cancer patients is described. eIF5A-1 and/or the eIF5A-2 isoform may serve as a new molecular diagnostic or prognostic marker or as a molecular target for anti-cancer therapy.
|
22139412 |
2013 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Combinatorial targeting of eIF5A hypusination and the RAS-ERK signaling pathway cooperated to attenuate KRAS expression and its downstream signaling along with cell growth <i>in vitro</i> and tumor formation <i>in vivo</i> Collectively, our findings highlight a new mechanistic strategy to attenuate KRAS expression as a therapeutic strategy to target PDAC and other human cancers driven by KRAS activation.<b>Significance:</b> These findings highlight a new mechanistic strategy to attenuate KRAS expression as a therapeutic strategy to target human cancers driven by KRAS activation.<i>Cancer Res; 78(6); 1444-56.©2018 AACR</i>.
|
29321164 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypusine modification of the eukaryotic initiation factor 5A (eIF-5A) is emerging as a crucial regulator in cancer, infections, and inflammation.
|
26037925 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fr-6 also could decrease the production level of eukaryotic translation initiation factor 5A, which is a potential cancer intervention target.
|
19995598 |
2010 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Eukaryotic initiation factor 5A (eIF5A), the only known cellular protein containing the amino acid hypusine, is an essential component of translation elongation. eIF5A2, one of the two isoforms in the eIF5A family, is reported to be a novel oncogenic protein in many types of human cancer.
|
24250246 |
2013 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
This review summarizes the mechanisms of polyamine regulation by canonical tumor suppressor genes and oncogenes, as well as the role of eukaryotic initiation factor 5A (EIF5A) in cancer.
|
21874756 |
2011 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The eukaryotic initiation factor 5A (eIF5A), which contributes to several crucial processes during protein translation, is the only protein that requires activation by a unique post-translational hypusine modification. eIF5A hypusination controls cell proliferation and has been linked to cancer. eIF5A hypusination requires the enzymes deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase and uniquely depends on the polyamine (PA) spermidine as the sole substrate.
|
29295892 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our findings indicate that eIF5A-PEAK1-YAP signaling contributes to PDAC development by regulating an STF program associated with increased tumorigenicity.<i>Cancer Res; 77(8); 1997-2007.©2017 AACR</i>.
|
28381547 |
2017 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of acute lymphoblastic leukemia cells to vincristine through inhibition of eif5a-2 activation.
|
28885268 |
2017 |
|
Parasitemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, mice infected with transgenic schizonts expressing either the eIF-5A or dhs shRNA showed an elevated parasitemia within the first two days post infection which then decreased intermittently.
|
22694849 |
2012 |
|
Pancreatic Neoplasm
|
0.010 |
Biomarker
|
disease |
LHGDN |
Heat stress-induced loss of eukaryotic initiation factor 5A (eIF-5A) in a human pancreatic cancer cell line, MIA PaCa-2, analyzed by two-dimensional gel electrophoresis.
|
11870779 |
2002 |
|
Pancreatic Ductal Adenocarcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In pancreatic ductal adenocarcinoma (PDAC), mutant KRAS stimulates the translation initiation factor eIF5A and upregulates the focal adhesion kinase PEAK1, which transmits integrin and growth factor signals mediated by the tumor microenvironment.
|
28381547 |
2017 |